Overview

Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy

Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to determine whether Valacyclovir treatment, administered during pregnancy after proven primary maternal Cytomegalovirus (CMV) infection, reduces fetal transmission rates and prevents fetal injury in cases of fetal infection.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Rabin Medical Center
Treatments:
Acyclovir
Valacyclovir
Criteria
Inclusion Criteria:

- Pregnant women over 18 years of age with serologically proven, primary CMV infection
during the first trimester of pregnancy or periconceptionally

Exclusion Criteria:

- Patients with preexisting liver disease, renal dysfunction, bone marrow suppression or
sensitivity to Acyclovir will be excluded from the study - as will patients receiving
any antiviral therapy prior to the study.